A Clinical Trial Evaluating SCB-219M in in Chemotherapy-induced Thrombocytopenia (CIT)
Phase 1
Recruiting
- Conditions
- Chemotherapy-induced Thrombocytopenia (CIT)
- Interventions
- Biological: Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Sichuan Clover Biopharmaceuticals, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT05426369
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- Sichuan Clover Biopharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT04123886
- Locations
- 🇨🇳
West China Hospitial, Sichuan University, Chengdu, Sichuan, China
Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites
- First Posted Date
- 2019-08-09
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- Sichuan Clover Biopharmaceuticals, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT04051112
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal Carcinomatosis
- First Posted Date
- 2019-08-07
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Sichuan Clover Biopharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04047771
- Locations
- 🇨🇳
Beijing Shijitan Hospital Capital Medical University, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath